Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe licensed weight loss injection medicines available in the UK — Mounjaro (tirzepatide) and Wegovy (semaglutide) — are both once-weekly injections, not daily. There is no daily injection approved in the UK for weight management, though it is one of the most common questions people ask before starting treatment. These are prescription-only medicines; a clinician assesses whether they are suitable for you before any prescription is issued. Understanding how the dosing schedule works, and what shapes that decision, is worth taking seriously before you begin.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It is easy to see why daily dosing feels intuitive. Most medicines taken for ongoing conditions (blood pressure tablets, for instance) are once a day, so the same logic seems to apply. Older weight-loss injections, including liraglutide (Saxenda), were indeed administered once daily. That medicine is no longer dispensed by nume, and the licensed landscape has moved on. The two medicines currently used for weight management through a UK regulated pharmacy are both once-weekly by design, not as a compromise.
The once-weekly schedule is not a simplification of something that would work better daily. Tirzepatide and semaglutide are both engineered with a long half-life, they remain pharmacologically active for roughly a week after each injection. Daily dosing would not improve results; it would change the risk profile without adding clinical benefit. That distinction matters when you are weighing up whether the schedule fits your life.
If you have read about how weight loss medication injections work more broadly, the mechanism helps explain this: these medicines bind to receptors involved in appetite signalling and blood-sugar regulation, and the sustained slow release is part of what makes the schedule practical for most people.
One of the first practical decisions you make when starting is which day of the week to inject. There is no medically superior option, the right day is the one you will actually remember and stick to. Some people find a Monday works well because it anchors the week; others prefer a Friday so any initial adjustment effects land over a weekend.
Once you have chosen, consistency matters more than the exact hour. If you normally inject on a Thursday morning but need to shift by a day (for travel, illness, or just a disrupted week) the Patient Information Leaflet and your prescriber will advise on the acceptable window. Exact timing guidance is something to take directly from the leaflet that comes with your medication, not from general articles like this one. The NHS page on tirzepatide on NHS.uk also covers missed-dose and timing questions clearly.
Injection sites rotate between the abdomen, thigh, and upper arm. Rotating prevents localised skin changes. If you are new to self-injection, it is less daunting than most people expect, a question our prescribers hear most weeks is whether it will be painful; the pens are designed for ease, with a very fine needle and, in some formats, a hidden needle mechanism. Our guide to injecting weight loss medication walks through the practical steps.
The once-weekly injection format suits most people, but it is not the only option. As of summer 2026, the MHRA approved the first oral GLP-1 medicine licensed for weight management in the UK: Wegovy tablets (oral semaglutide). It is taken once daily (before food, first thing in the morning) and requires no injection at all. If a needle is a real barrier rather than just an unfamiliar idea, it is worth knowing that a tablet route now exists.
Average weight loss in the OASIS 4 trial for the tablet, at 64 weeks, was around 13.6%, lower than the figures seen with the weekly injection at the same dose of semaglutide, but clinically meaningful. You can read more about non-injection weight loss medication options if that route appeals. The right choice depends on your health history, preferences, and what a prescriber concludes after a proper clinical review. No medicine in this class is suitable for everyone, and prescribers look at the full picture, not just BMI.
For context on what each option costs, the cost of weight loss injections page covers current private pricing without pretending the market is simple.
If you are deciding whether a once-weekly injection fits your life, the practical questions are fairly concrete: can you keep a pen refrigerated at home, do you travel frequently (there is a limited room-temperature window, check the SmPC or patient leaflet for the exact figure), and is self-injection something you are willing to learn? Most people find the routine settles quickly. The clinical questions (whether you are eligible, which medicine is more appropriate for your situation, what starting dose makes sense) are for a prescriber, not a search result.
The names of UK-licensed weight loss injection medicines and how they differ is a useful grounding before a consultation. So is a broader look at weight loss injections as a category. These are prescription-only medicines. NICE's appraisal of tirzepatide, TA1026, sets out the clinical criteria; your eligibility is confirmed by a prescriber who reviews your individual circumstances, not by a checklist you tick yourself.
When you are ready to find out whether treatment is suitable for you, start your free consultation with our prescribers, it is reviewed the same day by a real clinician, and there is no obligation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.